Company intelligence / Profile preview

Octant

Emeryville, California, United Statesoctant.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Octant has developed a proprietary high-throughput synthetic biology and chemistry platform to systematically map how small molecules interact with complex cellular mechanisms. Their approach enables the discovery of new small molecule drugs for diseases caused by protein misfolding/mistrafficking and other genetically validated but complex conditions. No clinical results have been published yet as their programs remain preclinical.

Therapeutic areas: ImmunologyOncologyRare Diseases
Modalities: Small moleculesSynthetic biology-enabled therapeuticsHigh-throughput screening platforms
Industry: Biotech

Drug pipeline

2 assets

OCT-980

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly announced as of May 2025.

Beyond the preview

Go deeper on Octant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Octant.

Explore the full profile